Aurinia Pharma Inc Live Stock Price Today, Share Analysis and Chart

Name: Aurinia Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Aurinia Pharmaceuticals Inc
Rating: 3.331249875
Author: Trendlyne DVM scores

Mid-range Performer

about

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...

14.53 -0.33 (-2.22%)

121.83% Gain from 52W Low

961.4K

XNAS Volume

XNAS 23 Jan, 2026 4:01 PM (EST)

High Financial Strength

83.3 / 100

Mid Valuation

44.3 / 100

Technically Neutral

55.5 / 100

Mid-range Performer These stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investors View Similar Embed DVM

1Yr Price target upside is 15%

6 analysts

Aurinia Pharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Aurinia Pharma Inc Live Stock Price Today, Share Analysis and Chart

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...

121.83% Gain from 52W Low

SWOT Analysis

Aurinia Pharma Inc Live Price Chart